No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FLGT240719P40000
- 11.63
- 0.000.00%
15min DelayTrading Jul 16 15:59 ET
0.00High0.00Low
0.00Open11.63Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover0.00%IV-29.72%PremiumJul 19, 2024Expiry Date18.13Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.88Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Jul. 11, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business
With 50% Ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) Boasts of Strong Institutional Backing
Press Release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the 'Company' or
What Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Share Price Doing?
Fulgent Data at ASCO 2024 Highlights Antitumor Activity From Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
EL MONTE, Calif.--(BUSINESS WIRE)--Jun. 3, 2024-- Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therap
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--May 24, 2024-- Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therap
Comments
Gainers:
• $Checkmate Pharmaceuticals(CMPI.US$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics(AXSM.US$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer(SMCI.US$ +14.3% (earnings report)
• $Plug Power(PLUG.US$ +9.24% (t...
• $Checkmate Pharmaceuticals(CMPI.US$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics(AXSM.US$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer(SMCI.US$ +14.3% (earnings report)
• $Plug Power(PLUG.US$ +9.24% (t...
16
1
Insider selling:
$VIZIO(VZIO.US$
$Fulgent Genetics(FLGT.US$
$Cara Therapeutics(CARA.US$
$KnowBe4, Inc.(KNBE.US$
$Coursera(COUR.US$
$Intellia Therapeutics(NTLA.US$
$Natera(NTRA.US$
$DraftKings(DKNG.US$
$Natural Alternatives International(NAII.US$
$Revolve Group(RVLV.US$
$A10 Networks(ATEN.US$
$Zuora(ZUO.US$
Insider Buying
$Spero Therapeutics(SPRO.US$
$Lumos Pharma(LUMO.US$
$Oscar Health(OSCR.US$
$Phibro Animal Health(PAHC.US$
$VIZIO(VZIO.US$
$Fulgent Genetics(FLGT.US$
$Cara Therapeutics(CARA.US$
$KnowBe4, Inc.(KNBE.US$
$Coursera(COUR.US$
$Intellia Therapeutics(NTLA.US$
$Natera(NTRA.US$
$DraftKings(DKNG.US$
$Natural Alternatives International(NAII.US$
$Revolve Group(RVLV.US$
$A10 Networks(ATEN.US$
$Zuora(ZUO.US$
Insider Buying
$Spero Therapeutics(SPRO.US$
$Lumos Pharma(LUMO.US$
$Oscar Health(OSCR.US$
$Phibro Animal Health(PAHC.US$
24
5
, thank you so much for information
$Fulgent Genetics(FLGT.US$ any idea why drop so much?
Read more
Silverbat : Buy at dips and hold for 192